Larissa TVM Francês

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
Background Chronic Myeloid Leukemia (CML) is a clonal myeloproliferative disorder characterized by formation of BCR-ABL fusion that encodes the p210 oncoprotein, which has a tyrosine kinase activity that confers an adaptive advantage to leukemic cells. Imatinib mesylate (IM) acts specifically on p210. Imatinib is able to reduce the differentiated cells(More)
  • 1